Blog / tracking
CJC-1295 and Ipamorelin Research: What Studies Show and What to Track
What published research on CJC-1295 and Ipamorelin reports, where the evidence is thin, and what to log in a peptide tracker under a provider's care.
By Peppy Team6 min read
CJC-1295 and Ipamorelin come up together so often that many people think of them as one product. They are two different peptides with two different research histories. Both are studied for the way they nudge the body's own growth hormone (GH) release, but they work through separate pathways and were tested in very different settings.
This post walks through what the published research on CJC-1295 and Ipamorelin actually reports, where the evidence is thin, and how to keep a clean peptide tracker record if a licensed provider has you on either one. It is an explainer, not advice. Whether either peptide makes sense for you, and how it would be used, is a decision for your provider.
What CJC-1295 and Ipamorelin are
CJC-1295
CJC-1295 is a lab-made version of growth hormone releasing hormone (GHRH). GHRH is the signal the brain sends to the pituitary gland to release GH. The natural hormone breaks down within minutes, which limits its use.
The version tested in the main human studies was built to attach to albumin, a protein in the blood. That attachment is what stretches out how long it lasts. You will often see this version labeled "CJC-1295 with DAC". The name CJC-1295 is also used loosely for a shorter acting version without that albumin binding part, so it helps to know which one a provider is talking about.
Ipamorelin
Ipamorelin is a small peptide made of five amino acids. It belongs to a group called GH secretagogues, which act on the ghrelin receptor rather than the GHRH receptor. In plain terms, CJC-1295 copies one "release GH" signal, and Ipamorelin copies a different one.
What the research on CJC-1295 reports
The best known human data come from a 2006 study in the Journal of Clinical Endocrinology and Metabolism by Teichman and colleagues. It ran two randomized, placebo controlled trials in healthy adults aged 21 to 61. The researchers reported:
- After a single injection, average GH levels rose 2 to 10 fold for six days or more.
- Average IGF-1 levels (a marker that follows GH activity) rose 1.5 to 3 fold for 9 to 11 days.
- The estimated half-life was about 5.8 to 8.1 days.
- No serious adverse reactions were reported in those trials.
A follow up study by the same research group looked at overnight GH patterns and found that the natural pulse pattern of GH release was preserved, while the lowest (trough) levels between pulses went up.
What these studies do not show
These were short studies in a small number of healthy volunteers. They measured hormone levels in the blood. They did not measure long term outcomes such as body composition, recovery, sleep or aging, which are the claims you often see online. Those claims are not what this research tested.
What the research on Ipamorelin reports
The early lab work
Ipamorelin was described in a 1998 paper in the European Journal of Endocrinology by Raun and colleagues at Novo Nordisk. In lab and animal testing, it released GH with potency similar to an older peptide called GHRP-6. The finding that drew attention was selectivity. In the animal tests, Ipamorelin did not raise ACTH or cortisol (stress related hormones) in a meaningful way, even at very high amounts, while the older peptides did. The authors called it the first selective GH secretagogue.
That selectivity is a big part of why Ipamorelin is discussed so often. It is worth remembering that this was animal and cell research, not a study in people.
The human trial
The largest published human trial is a 2014 phase 2 study by Beck and colleagues. It tested Ipamorelin in 114 adults after bowel surgery, looking at whether it helped the gut recover faster (a problem called postoperative ileus).
The results were mixed:
- Ipamorelin was reported as well tolerated.
- The median time to tolerating a solid meal was about 25 hours with Ipamorelin and about 33 hours with placebo.
- That gap was not statistically significant, and there were no significant differences in the main or secondary results.
So the one sizable human trial did not show a clear benefit for the question it asked.
Why they are often paired
The common reasoning is that two different signals may add together. CJC-1295 acts on the GHRH receptor, and Ipamorelin acts on the ghrelin receptor. In theory, triggering both pathways could produce a larger GH response than either alone.
That idea comes from how the pathways work. We did not find a published human trial that tested the CJC-1295 and Ipamorelin combination itself. If you see firm claims about what the pair "does", treat them as marketing until someone shows you the study.
CJC-1295 vs Ipamorelin at a glance
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Type | GHRH analog | GH secretagogue (ghrelin receptor) |
| Main human data | Short trials in healthy adults (2006) | Phase 2 trial after bowel surgery (2014) |
| What was measured | GH and IGF-1 blood levels | Gut recovery time and safety |
| Key finding | Long lasting rise in GH and IGF-1 | Well tolerated, no significant benefit vs placebo |
| Big gap | No long term outcome data | Selectivity shown mainly in animals |
What to track if your provider has you on them
Because the evidence is limited, a careful personal record matters more, not less. It is the main thing you and your provider have to go on. A peptide tracker helps you keep that record consistent instead of rebuilding it from memory before each appointment.
Doses as given
Log each dose exactly as your provider gave it, with the date and time. If you are on a blend in one vial, note that it is a blend and what the label says is in it. Record missed or late doses honestly. A pattern of late doses is useful information, not a failure.
Vial details
For powder vials, write down the vial strength from the label, how much water was added, and the date you mixed it. These three numbers decide how many units on the syringe match the dose your provider gave you. The free peptide calculator on our site does that math from the vial strength, water added and your dose, and it includes CJC-1295, Ipamorelin and a CJC + Ipamorelin blend in its list. It shows the numbers only. It does not suggest what to take.
How you feel
Note sleep, energy, appetite, water retention, tingling, headaches or anything at the injection site, with a simple mild, moderate or severe rating. Do not try to interpret these yourself. Bring the log to your provider and let them read the trend. If anything feels serious, contact them promptly rather than waiting for the next visit.
Labs and appointments
If your provider orders blood work such as IGF-1, add the date of each test to your notes so results can be matched to your dose history. Write down questions as they come up so you remember them at the visit.
Keeping a record in Peppy
Peppy is a peptide tracker app for iPhone that keeps these pieces in one place. You enter the vial and the dose your provider gave you, and it can send dose reminders, count down what is left in each vial with the vial tracker, and suggest a rested spot through injection site rotation. If your provider has you on and off cycles, the titration and cycles setup records the plan they gave you. Side effect check-ins sit next to your doses in your history, so the timeline is easy to show at an appointment.
The short version
CJC-1295 has small human studies showing it raises GH and IGF-1 for days at a time. Ipamorelin has encouraging animal data on selectivity and one human trial that did not meet its main goal. The popular pairing rests on theory more than direct evidence. If you and your provider decide to use either, keep a steady, honest log of doses, vials and how you feel, and let your provider judge what it means.
More from the blog

dose log6 min read
BPC-157 Tracker: Logging Injections, Sites and How You Feel
A practical guide to using a BPC-157 tracker: what to log at every injection, how to keep vial math straight and how to record sites and symptoms.
- dose log
- injection sites
- vials

tracking6 min read
Tesamorelin Research Explained: What Studies Show and What to Track
What FDA-approved tesamorelin studies show for HIV lipodystrophy, key limits of use, and what a peptide tracker app should record.
- tracking
- dose log
- vials

tracking6 min read
TB-500 Research Explained: What Studies Show and What to Track
What TB-500 and thymosin beta-4 studies actually show, where evidence is thin, and what a peptide tracker should record with your provider.
- tracking
- dose log
- side effects
